The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Aptamer to ErbB-2/HER2 enhances degradation of the target and inhibits tumorigenic growth
Open accessAbstract
Aptamers, oligonucleotides able to avidly bind cellular targets, are emerging as promising therapeutic agents, analogous to monoclonal antibodies. We selected from a DNA library an aptamer specifically recognizing human epidermal growth factor receptor 2 (ErbB-2/HER2), a receptor tyrosine kinase, which is overexpressed in a variety of human cancers, including breast and gastric tumors. Treatment of human gastric cancer cells with a trimeric version (42 nucleotides) of the selected aptamer (14 nucleotides) resulted in reduced cell growth in vitro, but a monomeric version was ineffective. Likewise, when treated with the trimeric aptamer, animals bearing tumor xenografts of human gastric origin reflected reduced rates of tumor growth. The antitumor effect of the aptamer was nearly twofold stronger than that of a monoclonal anti–ErbB-2/HER2 antibody. Consistent with aptamer-induced intracellular degradation of ErbB-2/HER2, incubation of gastric cancer cells with the trimeric aptamer promoted translocation of ErbB-2/HER2 from the cell surface to cytoplasmic puncta. This translocation was associated with a lysosomal hydrolase-dependent clearance of the ErbB-2/HER2 protein from cell extracts. We conclude that targeting ErbB-2/HER2 with DNA aptamers might retard the tumorigenic growth of gastric cancer by means of accelerating lysosomal degradation of the oncoprotein. This work exemplifies the potential pharmacological utility of aptamers directed at cell surface proteins, and it highlights an endocytosis-mediated mechanism of tumor inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In fact, it has become possible to perform natural selection on oligonucleotides by iterative amplification and selection processes using a technique called systematic evolution of ligands by exponential enrichment, or SELEX.”
From Towards open-ended evolution in self-replicating molecular systems (2017) · cites this paper as [43]
Citations
Cites
Tuerk, C., & Gold, L. (1990) · Science · doi:10.1126/science.2200121 · Cited by 10,421
In vitro selection of RNA molecules that bind specific ligands
Ellington, A. D., & Szostak, J. W. (1990) · Nature · doi:10.1038/346818a0 · Cited by 9,845
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citationInhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
EGFR Antagonists in Cancer Treatment
Ciardiello, F., & Tortora, G. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707704 · Cited by 2,095
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,667
SELEX—A (r)evolutionary method to generate high-affinity nucleic acid ligands
Stoltenburg, R., Reinemann, C., & Strehlitz, B. (2007) · Biomolecular Engineering · doi:10.1016/j.bioeng.2007.06.001 · Cited by 1,485
Analytical applications of aptamers
Tombelli, S., Minunni, M., & Mascini, M. (2004) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2004.11.006 · Cited by 1,020
Dassie, J. P., Liu, X., Thomas, G. S., Whitaker, R. M., Thiel, K. W., Stockdale, K. R., Meyerholz, D. K., McCaffrey, A. P., McNamara, J. O., & Giangrande, P. H. (2009) · Nature Biotechnology · doi:10.1038/nbt.1560 · Cited by 600
Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding
Bates, P. J., Kahlon, J. B., Thomas, S. D., Trent, J. O., & Miller, D. M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.37.26369 · Cited by 407
Cited by
Sorted by citations
Items 101–169 of 169
Ma, X., Yan, J., Zhou, G., Li, Y., Ran, M., Li, C., Chen, X., Sun, W., Zhang, H., & Shen, X. (2024) · Advanced Functional Materials · doi:10.1002/adfm.202406650 · Cited by 15
Advancing Autonomous Nanomedicine: Bridging the Gap from Concept to Potential Clinical Studies
Chohan, D. P., Dey, B., Tarkunde, A., Vyas, V., Sarkar, S. D., & Babitha, K. S. (2024) · Journal of Cluster Science · doi:10.1007/s10876-024-02691-0 · Cited by 18
Clua, A., Fàbrega, C., García-Chica, J., Grijalvo, S., & Eritja, R. (2021) · Molecules · doi:10.3390/molecules26061741 · Cited by 15
Aptamer-Functionalized Gold Nanostars for on-Demand Delivery of Anticancer Therapeutics
Wu, D., Zhao, P., Wu, L., Lin, L., Yu, G., Xu, L., & Yue, J. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00499 · Cited by 15
RNA therapeutics in cancer treatment
Nguyen, M. N., & Than, V. T. (2024) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2024.01.003 · Cited by 13
Kneißle, K., Krämer, M., Kissmann, A., Hu, X., Müller, F., Amann, V., Noschka, R., Gottschalk, K., Bozdogan, A., Andersson, J., et al. (2022) · Journal of Fungi · doi:10.3390/jof8080856 · Cited by 15
Goh, K. W., Stephen, A., Wu, Y. S., Sim, M. S., Batumalaie, K., Gopinath, S. C. B., Guad, R. M., Kumar, A., Sekar, M., Subramaniyan, V., et al. (2023) · Journal of Cancer · doi:10.7150/jca.85260 · Cited by 14
Guo, Y., Liu, F., Hu, Y., Zheng, X., Cao, X., Zhu, Y., Zhang, X., Li, D., Zhang, Z., & Chen, S. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.9b00787 · Cited by 13
Tan, Y. H., Peng, Y., Ai, L., Li, Y., Qu, Y.-X., Wang, D., Su, Y., Deng, T., Fu, T., Zhao, Z., et al. (2020) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.0c00250 · Cited by 13
Nucleic Acid-Based Treatments Against COVID-19: Potential Efficacy of Aptamers and siRNAs
Khanali, J., Azangou‐Khyavy, M., Asaadi, Y., Jamalkhah, M., & Kiani, J. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.758948 · Cited by 15
Wu, Z., Wu, C., Cai, K., Huang, Z., Huang, J. D., Wu, Z., & Zhao, Z. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c03000 · Cited by 12
Therapeutic Application of Drug-Conjugated HER2 Oligobody (HER2-DOligobody)
Kim, H. J., Sung, H. J., Lee, Y. M., Choi, S. I., Kim, Y., Heo, K., & Kim, I.-H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093286 · Cited by 12
Nuclear Medicine for Imaging of Epithelial Ovarian Cancer
Abedi, S. M., Mardanshahi, A., Shahhosseini, R., & Hosseinimehr, S. J. (2016) · Future Oncology · doi:10.2217/fon.16.19 · Cited by 11
Multimerization of ERBB2/HER2 specific aptamer leads to improved receptor binding
Mahlknecht, G., Maron, R., Schechter, B., Yarden, Y., & Sela, M. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.07.157 · Cited by 11
Self-citationGuo, W. M., Kong, K. W., Brown, C. J., Quah, S. T., Yeo, H. L., Hoon, S. S., & Seow, Y. (2014) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2014.70 · Cited by 11
Aptamer Targeting the ERBB2 Receptor Tyrosine Kinase for Applications in Tumor Therapy
Mahlknecht, G., Sela, M., & Yarden, Y. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2727-2_1 · Cited by 11
Self-citationBoonkaew, S., Teodori, L., Vendelbo, M. H., Kjems, J., & Ferapontova, E. E. (2024) · Analytica Chimica Acta · doi:10.1016/j.aca.2024.343472 · Cited by 10
Site-specific DNA functionalization through the tetrazene-forming reaction in ionic liquids
Ishizawa, S., Tumurkhuu, M., Gross, E. J., & Ohata, J. (2022) · Chemical Science · doi:10.1039/d1sc05204g · Cited by 10
Zheng, T., Rigby, L. G., Marshall, J. F., & Palma, M. (2025) · ACS Nano · doi:10.1021/acsnano.5c07581 · Cited by 9
Covalent aptamers: agents with promising therapeutic and diagnostic potential
Albright, S., Boette, J., Cacace, M., & Deiters, A. (2025) · RSC Chemical Biology · doi:10.1039/d5cb00133a · Cited by 9
Díaz‐Fernández, A., & Ferapontova, E. E. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2022.340049 · Cited by 9
Kissmann, A., Wolf, D., Krämer, M., Müller, F., Amann, V., Hu, X., Gottschalk, K., Weil, T., Eichmann, R., Schäfer, P., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012220 · Cited by 9
López‐Laguna, A., Polonio, Á., Castro, L. J., Morales, Y., Vielba‐Fernández, A., Martín, M. E., González, V. M., de Vicente, A., Pérez‐García, A., & Fernández‐Ortuño, D. (2025) · Plant Biotechnology Journal · doi:10.1111/pbi.70317 · Cited by 8
High-Curvature Features on Branched Nanoconstructs Circumvent Protein Corona Interference
Diloknawarit, B., Schaumann, E. N., & Odom, T. W. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c00725 · Cited by 8
Biodistribution of Novel 68Ga-Radiolabelled HER2 Aptamers in Mice
Gijs, M., Becker, G., & Plenevaux, A. (2016) · Journal of Nuclear Medicine & Radiation Therapy · doi:10.4172/2155-9619.1000300 · Cited by 7
Construction of pH/reduction dual responsive MSN-HAgel containing HApt for tumor targeting carriers
Liu, Y., Chen, M., Li, G., Xu, S., & Liu, H. (2022) · RSC Advances · doi:10.1039/d2ra02290g · Cited by 7
Brown, T. M., Saliba, D., Hartmann, J., Asohan, J., Yao, C., Das, T., & Sleiman, H. F. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c02986 · Cited by 6
Multifaceted arsenal in SELEX nanomedicine
Chatterjee, O., Kaur, G. A., Shukla, N., Balayan, S., Singh, P. K., Chatterjee, S., & Tiwari, A. (2025) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2025.103540 · Cited by 7
Peng, L., Ye, F., Zhang, R., Du, Y., Liu, Q., Zhang, R., Zhang, B., & Chen, T. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c03404 · Cited by 6
A Single Extracellular Vesicle (EV) Flow Cytometry Approach to Reveal EV Heterogeneity
Shen, W., Guo, K., Adkins, G. B., Jiang, Q., Liu, Y., Sedano, S., Duan, Y., Yan, W., Wang, S. E., Bergersen, K. V., et al. (2018) · Angewandte Chemie · doi:10.1002/ange.201806901 · Cited by 5
Moving towards Personalized Medicine—The Broad Use of Aptamers for Targeted Theranostic
Sousa, A. P., Rocha, A. C., Almeida, C., Carneiro, M. C. C. G., Pais, P. P., Viana, R., Fernandes, R., Barata, P., Gestoso, Á., Ramalho, S., et al. (2023) · Applied Sciences · doi:10.3390/app132111933 · Cited by 5
Aptasensors for Cancerous Exosome Detection
Li, J., Xie, S., Qu, F., & Tan, W. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2341-1_1 · Cited by 5
Theranostic potential of a novel aptamer specifically targeting HER2 in breast cancer cells
KÜÇÜKCANKURT, F., Uçak, S., & Altıok, N. (2024) · TURKISH JOURNAL OF BIOLOGY · doi:10.55730/1300-0152.2680 · Cited by 4
Molenda, S., Deptuch, T., Sikorska, A., Lorenc, P., Smialek, M. J., Florczak, A., Pawlak, P., & Dams‐Kozlowska, H. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s519906 · Cited by 3
Bai, X., Wang, Y., Zhang, X., Niu, C., Yang, G., Yuan, D., Wei, Y., Zheng, L., Song, X., Bao, Y., et al. (2025) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2025.102866 · Cited by 3
Aptamer-Based Targeted Drug Delivery Systems
Tiwari, R., Gulbake, A., Kumar, P., Gulbake, A. S., Gupta, R., Bisht, D., & Sethiya, N. K. (2022) · Nanotechnology in the life sciences · doi:10.1007/978-3-031-12658-1_4 · Cited by 3
Navyatha, B., & Nara, S. (2023) · Journal of Nanoparticle Research · doi:10.1007/s11051-023-05808-0 · Cited by 3
Malik, I. S., Nair, N. K., Athira, B., Mishra, S., Unnithan, S., Narayana, C., & Bhowmik, D. (2025) · Langmuir · doi:10.1021/acs.langmuir.5c00350 · Cited by 3
Guo, R., Chen, X., Ying, L., Zhang, W., Sabeel, Z., Zhao, L., Dong, J., Dong, Y., & Zhao, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1557910 · Cited by 3
Das, V., Chikkaputtaiah, C., & Pal, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-08-102555-0.00014-5 · Cited by 3
Lü, X., He, J., Li, X., & Zhao, Y. (2013) · OncoImmunology · doi:10.4161/onci.26295 · Cited by 2
Discovery of tumoricidal DNA oligonucleotides by response-directed in vitro evolution
Mamet, N., Amir, Y., Lavi, E., Bassali, L., Harari, G., Rusinek, I., Skalka, N., Debby, E., Greenberg, M., Zamir, A., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-0756-0 · Cited by 2
Emrani, S., Lamar, M., Price, C. C., Baliga, S., Wasserman, V., Matusz, E. F., Swenson, R., Baliga, G. R., & Libon, D. J. (2021) · Exploration of Medicine · doi:10.37349/emed.2021.00034 · Cited by 2
Aptamers in biosensing: biological characteristics and applications
Giannetti, A. E., Adinolfi, B., & Tombelli, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-85881-6.00008-7 · Cited by 2
Yang, G. H., & Huang, Y. (2021) · Springer eBooks · doi:10.1007/978-981-33-4838-7_6 · Cited by 1
Selection and Optimization of a High-Affinity FGFR4 Aptamer that Blocks FGF19–FGFR4 Signaling
Zhao, X., Long, Z., Liu, X. D., Zhang, X., Wu, M. T., Lin, H., Zhang, M., Hua, Y., & Bing, T. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c00079 · Cited by 1
Chen, K., Cai, J., Wang, S., Li, Y., Yang, C., Fu, T., Zhao, Z., Zhang, X., & Tan, W. (2022) · Angewandte Chemie · doi:10.1002/ange.202208451 · Cited by 1
Zhang, L., Li, Y., Zhai, L., Tang, Y., Jiao, Y., Mei, Y., Yang, R., You, R., Yin, L., Ni, H., et al. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00756 · Cited by 1
The Screening of Aptamer-Gastric Cancer for Targeting Gastric Cancer Cells
Xiao, X., Xiang, Y.-F., Xiang, Y., Zhou, C., Sun, G., Qin, B., Wan, Z., Li, J., Yu, X., Xu, J., et al. (2025) · Frontiers in Bioscience-Landmark · doi:10.31083/fbl37734 · Cited by 1
Liu, W. R., Cao, L., & Zuo, G. (2016) · Genetics and Molecular Research · doi:10.4238/gmr15048860 · Cited by 1
KÜÇÜKCANKURT, F., & Altıok, N. (2020) · AYDIN TIP FAKÜLTESİ KLİNİKLERİ DERGİSİ · doi:10.17932/iau.tfk.2018.008/2020.301/tfk_v03i1005 · Cited by 1
Discovery of tumoricidal DNA oligonucleotides by effect-directed in-vitro evolutionPreprint
Mamet, N., Amir, Y., Lavi, E., Bassali, L., Harari, G., Rusinek, I., Skalka, N., Debby, E., Greenberg, M., Zamir, A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/629105 · Cited by 1
Aptamer: “smart bomb” facilitates delivery of drugs to the cancer cells
Patel, N. V., & Vadgama, N. S. (2015) · Pharmaceutical and Biological Evaluations
Expanding the Chemical Repertoire of DNA Nanomaterials Generated by Rolling Circle AmplificationPreprint
Baker, Y. R., Yuan, L., Chen, J., Belle, R., Carlisle, R. C., El-Sagheer, A. H., & Brown, T. P. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12566963
Chen, S., Li, J., & Yang, H. (2024) · Wiley eBooks · doi:10.1002/9783527840816.ch13
Advances in aptamer technology and its updated applications in gastric cancer
Hosseini, S. A., Nejad, A. R., Valadbeigi, H., Haddadi, M. H., & Bazdar, M. (2025) · Analytical Biochemistry · doi:10.1016/j.ab.2025.115950
Aptamer: A Targeted Cancer Immuno Therapy
Kasar, G. N., & Rasal, P. B. (2025) · Asian Journal of Pharmaceutical Research · doi:10.52711/2231-5691.2025.00044
Chen, S., Zhuo, Y., Pang, L., Liang, H., Lin, X., & Li, J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c20326
Bispecific aptamers inhibit tumor growth by inducing degradation of multiple kinases
Wu, S., Xie, T., Yuan, Y., Yan, Y., Zhou, X., Shang, Y., Zhou, A., Chen, K., Zhao, Z., & Tan, W. (2026) · Science China Chemistry · doi:10.1007/s11426-025-3121-y
Current advances in aptamer-based PET imaging
Guo, J., Gao, T., Wu, H., Yun, H., Zou, S., Sun, M., & Sun, X. (2026) · Journal of Nuclear Medicine and Molecular Imaging · doi:10.65457/jnmmi-2026-0011
AptCancerDB: A Curated Knowledgebase and Translational Discovery Platform for Anticancer AptamersPreprint
Bajiya, N., Singh, S. S., & Raghava, G. P. S. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.02.735999 · Cited by 1
In Situ SERS Monitoring of Membrane Protein Homo- and Hetero-Dimerizations at the Single-Cell Level
Dong, C., Fang, X., Wang, T., Zhang, J., He, X., Liu, J., Wang, L., & Song, C. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c01783
Lv, Y., Liu, Z., Meng, X., Jiang, P., Qu, J., Jiang, Y., Qiu, B., Chen, J., & Chen, P. (2026) · Advanced Science · doi:10.1002/advs.77177
Gong, X., Han, Y., Fang, Y., & Song, M. (2026) · Angewandte Chemie · doi:10.1002/ange.7162372
Gong, X., Han, Y., Fang, Y., & Song, M. (2026) · Angewandte Chemie International Edition · doi:10.1002/anie.7162372
Yu, C., Chen, Z., Liu, J., Shi, X., Xie, W., Zeng, L., Zhang, M., Wang, S., Zhang, S., & Huang, A. (2026) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2026.141749
Wu, H.-B., Zeng, Z., Huang, W., Lin, X., Tian, R., Chen, J., & Zhang, Q.-L. (2026) · Biosensors · doi:10.3390/bios16100549
Meng, X., Zhang, Z., Jiang, P., Qiu, B., Chen, J., & Chen, P. (2026) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2026.119312
Metadata
- Authors
- Mahlknecht, G., Maron, R., Mancini, M., Schechter, B., Sela, M., & Yarden, Y.
- Affiliations
- Weizmann Institute of Science (IL)
- Departments of aImmunology and
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-04-29
- Volume
- 110
- Issue
- 20
- Pages
- 8170-8175
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3657787
- OpenAlex
- W2062141406
- Cited by
- 169
- References
- 26
- Citations by year
- 2026: 11 · 2025: 16 · 2024: 14 · 2023: 10 · 2022: 16 · 2021: 13 · 2020: 15 · 2019: 14 · 2018: 16 · 2017: 10 · 2016: 8 · 2015: 12 · 2014: 13 · 2013: 1
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA072981, R01CA072981, R37CA072981)
- Topics
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Keywords
- DNA aptamers, gastric cancer, lysosomal degradation, receptor tyrosine kinase, endocytosis, tumor growth inhibition, cell surface translocation, aptamer therapeutics
- MeSH terms
- Animals, Antineoplastic Agents, Cross-Linking Reagents, Cytoplasm, DNA, Female, Humans, Lysosomes, Mice, Nude, Neoplasm Transplantation, Nucleotides, Protein Binding, Stomach Neoplasms, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, Cell Line, Tumor, Cell Proliferation, Mice, Aptamers, Nucleotide
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
